• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泰国HIV-1感染成年患者中血浆依非韦伦浓度低于治疗水平的药物遗传学及临床生物标志物

Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.

作者信息

Sukasem Chonlaphat, Chamnanphon Montri, Koomdee Napatrupron, Santon Siwalee, Jantararoungtong Thawinee, Prommas Santirat, Puangpetch Apichaya, Manosuthi Weerawat

机构信息

Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University.

出版信息

Drug Metab Pharmacokinet. 2014;29(4):289-95. doi: 10.2133/dmpk.dmpk-13-rg-077. Epub 2014 Jan 28.

DOI:10.2133/dmpk.dmpk-13-rg-077
PMID:24477223
Abstract

The aim of this study was to assess the influence of host genetic variations and clinical factors in relation to efavirenz level in HIV-1 infected Thai adults. A total of 100 HIV-infected subjects treated with efavirenz/lamivudine/tenofivir were prospectively enrolled. The panel of CYP2A6, CYP2B6 and CYP3A4/5 polymorphisms was genotyped. At steady state, plasma efavirenz concentrations were measured using high performance liquid chromatography. The relationship between host genetic and clinical factors in terms of efavirenz pharmacokinetics in HIV-1 infected Thai adults was analyzed. The minor allele frequency for CYP2A6 -48T>G, CYP2B6 g.18492T>C, CYP3A41B c.-392A>G, CYP3A418 c.878T>C and CYP3A53 c.6986A>G was 0.14, 0.27, 0.01, 0.03 and 0.38, respectively. Univariant and multivariant analysis indicated associations for CYP2B6 g.18492T>C (p < 0.001 and p = 0.001), aspartate aminotransferase (AST; p = 0.001 and p = 0.006) and blood urea nitrogen (BUN; p = 0.011 and p = 0.016) with plasma efavirenz concentration. However, CYP2A6 -48T>G, CYP3A41B c.-392A>G, CYP3A418 c.878T>C and CYP3A53 c.6986A>G had no significant impact on plasma efavirenz concentration in HIV-1 infected Thai adults. The CYP2B6 g.18492T>C polymorphism, AST and BUN were significantly associated with low efavirenz concentrations. The results from this study can be used to improve the prediction of efavirenz plasma concentration and to optimize its dose in antiretroviral therapy.

摘要

本研究的目的是评估宿主基因变异和临床因素对感染HIV-1的泰国成年人中依非韦伦水平的影响。前瞻性纳入了100例接受依非韦伦/拉米夫定/替诺福韦治疗的HIV感染受试者。对CYP2A6、CYP2B6和CYP3A4/5多态性进行基因分型。在稳态时,使用高效液相色谱法测量血浆依非韦伦浓度。分析了感染HIV-1的泰国成年人中宿主基因和临床因素在依非韦伦药代动力学方面的关系。CYP2A6 -48T>G、CYP2B6 g.18492T>C、CYP3A41B c.-392A>G、CYP3A418 c.878T>C和CYP3A53 c.6986A>G的次要等位基因频率分别为0.14、0.27、0.01、0.03和0.38。单变量和多变量分析表明,CYP2B6 g.18492T>C(p < 0.001和p = 0.001)、天冬氨酸转氨酶(AST;p = 0.001和p = 0.006)和血尿素氮(BUN;p = 0.011和p = 0.016)与血浆依非韦伦浓度相关。然而,CYP2A6 -48T>G、CYP3A41B c.-392A>G、CYP3A418 c.878T>C和CYP3A53 c.6986A>G对感染HIV-1的泰国成年人血浆依非韦伦浓度没有显著影响。CYP2B6 g.18492T>C多态性、AST和BUN与依非韦伦低浓度显著相关。本研究结果可用于改善依非韦伦血浆浓度的预测,并优化其在抗逆转录病毒治疗中的剂量。

相似文献

1
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.泰国HIV-1感染成年患者中血浆依非韦伦浓度低于治疗水平的药物遗传学及临床生物标志物
Drug Metab Pharmacokinet. 2014;29(4):289-95. doi: 10.2133/dmpk.dmpk-13-rg-077. Epub 2014 Jan 28.
2
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.CYP2B6 基因多态性标志物、临床因素和药物相互作用对 HIV/结核分枝杆菌共感染患者中依非韦伦浓度的影响。
Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17.
3
High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.南非 HIV/AIDS 患者中 CYP2B6 单核苷酸多态性对稳态血浆依非韦伦水平的高预测价值。
Pharmacogenet Genomics. 2013 Aug;23(8):415-27. doi: 10.1097/FPC.0b013e328363176f.
4
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.南非成人和儿童HIV感染者血浆依法韦仑暴露的药物遗传学
Br J Clin Pharmacol. 2015 Jul;80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 28.
5
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.HIV感染的携带CYP2B6慢代谢基因型的成年患者的次生代谢途径多态性与血浆依法韦仑浓度
J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.
6
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.细胞色素P450 2B6(CYP2B6)基因18492位点的T→C多态性会降低携带CYP2B6单倍型*1/*1的HIV合并结核感染患者体内依非韦伦的血药浓度。
Antimicrob Agents Chemother. 2014;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.
7
High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.高血浆依非韦伦浓度和泰国 HIV-1 感染中 CYP2B6 多态性。
Drug Metab Pharmacokinet. 2013;28(5):391-7. doi: 10.2133/dmpk.dmpk-12-rg-120. Epub 2013 Feb 12.
8
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.CYP2B6 相关的药物遗传学标记物与 HIV-1 感染泰国成年人中依非韦伦的血浆浓度相关。
Br J Clin Pharmacol. 2012 Dec;74(6):1005-12. doi: 10.1111/j.1365-2125.2012.04288.x.
9
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.在加纳 HIV 感染患者的回顾性队列中,药物遗传学与血浆依非韦伦浓度和临床相关因素的关联。
J Antimicrob Chemother. 2014 Feb;69(2):491-9. doi: 10.1093/jac/dkt372. Epub 2013 Sep 29.
10
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.接受含依非韦伦抗逆转录病毒治疗且接受或未接受基于利福平抗结核治疗的华裔HIV感染者的治疗药物监测和药物遗传学研究
PLoS One. 2014 Feb 14;9(2):e88497. doi: 10.1371/journal.pone.0088497. eCollection 2014.

引用本文的文献

1
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.用于改善新冠病毒疾病治疗的药物遗传学和精准医学方法。
Front Pharmacol. 2022 Feb 18;13:835136. doi: 10.3389/fphar.2022.835136. eCollection 2022.
2
Influence of Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients.多态性对泰国HIV-1患者血浆依法韦仑浓度的影响。
Pharmgenomics Pers Med. 2021 Jul 24;14:915-926. doi: 10.2147/PGPM.S306358. eCollection 2021.
3
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
临床药物遗传学实施联盟(CPIC)指南:CYP2B6 和含依非韦伦的抗逆转录病毒治疗。
Clin Pharmacol Ther. 2019 Oct;106(4):726-733. doi: 10.1002/cpt.1477. Epub 2019 Jul 5.
4
Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.遗传变异对避孕埋植剂使用者中依托孕烯稳态浓度的影响。
Obstet Gynecol. 2019 Apr;133(4):783-794. doi: 10.1097/AOG.0000000000003189.
5
Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.细胞色素P450基因多态性与博茨瓦纳一个HIV队列中依非韦伦广泛的药代动力学及中枢神经系统毒性相关。
Pharmacogenomics J. 2018 Sep;18(5):678-688. doi: 10.1038/s41397-018-0028-2. Epub 2018 Jun 1.
6
Variation in CYP2A6 Activity and Personalized Medicine.CYP2A6活性的变异与个性化医疗
J Pers Med. 2017 Dec 1;7(4):18. doi: 10.3390/jpm7040018.
7
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.泰国将药物遗传学应用于临床实践以治疗艾滋病毒感染者。
Pharmgenomics Pers Med. 2015 Nov 5;8:163-70. doi: 10.2147/PGPM.S86444. eCollection 2015.
8
PharmGKB summary: Efavirenz pathway, pharmacokinetics.药物基因组学知识库总结:依非韦伦途径,药代动力学。
Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145.